PTGX · ISSUER CIK 1377121
Protagonist Therapeutics, Inc
Between Aug 1, 2026 and Oct 29, 2026, 2 Protagonist Therapeutics, Inc insiders reported $0.00 of open-market purchases and $41.4M of sales on SEC Form 4.
↗2 insiders filed
Original Form 4 filings from Aug 1, 2026 to Oct 29, 2026. 3 of 3 sales were reported under a 10b5-1 plan.
$0.00Insider buying
$41.4MInsider selling
−$41.4MNet open-market
Oct 2, 2026Latest filing
| Ticker | Insider | Type | Owned | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Oct 2, 202616:10 | Sep 30, 2026 | PTGX | Chief Financial Officer | S · Sell10b5-1 | $141.78 | −58,629 | 59,003 | -50% | −$8.3M | ||
| Oct 2, 202616:10 | Sep 30, 2026 | PTGX | Chief Financial Officer | M · Exercise10b5-1 | $23.72 | +58,629 | 117,632 | +99% | $1.4M | ||
| Sep 10, 202621:17 | Sep 10, 2026from Sep 8, 2026 | PTGX | President and CEO, Director | S · Sell10b5-1 | $145.92 | −125,000 | 522,968 | -19% | −$18.2M | ||
| Sep 10, 202621:17 | Sep 10, 2026from Sep 8, 2026 | PTGX | President and CEO, Director | M · Exercise10b5-1 | $21.58 | +125,000 | 530,246 | +31% | $2.7M | ||
| Sep 8, 202617:14 | Sep 3, 2026 | PTGX | President and CEO, Director | G · GiftLate 5d | — | −510 | 522,968 | -0% | — | ||
| Aug 12, 202618:43 | Aug 11, 2026from Aug 10, 2026 | PTGX | President and CEO, Director | S · Sell10b5-1 | $148.91 | −100,000 | 523,478 | -16% | −$14.9M | ||
| Aug 12, 202618:43 | Aug 11, 2026from Aug 10, 2026 | PTGX | President and CEO, Director | M · Exercise10b5-1 | $21.58 | +100,000 | 557,717 | +22% | $2.2M |